Clinical Trials Logo
  1. Home
  2. Mastocytosis
  3. NCT05084872

Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients — HCQMa  

Mastocytosis Clinical Trial

Official title:
Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients: Proof of Concept Study

Clinical Trial Summary

The treatment of systemic mastocytosis has two main axes: - Control of mast cell activation symptoms and - The control of proliferation (accumulation) of mast cells. There is no standard treatment and no treatment has a marketing authorization for the treatment of monoclonal indolent mastocytosis.

Clinical Trial Description

Mastocytosis is an orphan disease related to the accumulation and / or the proliferation of abnormal mast cells in different tissues. In adults, a classic distinction is made between isolated cutaneous forms (10 to 15%) and systemic forms (85 to 90%). The treatment of systemic mastocytosis has two main axes: - Control of mast cell activation symptoms and - The control of proliferation (accumulation) of mast cells. There is no standard treatment and no treatment has a marketing authorization for the treatment of monoclonal indolent mastocytosis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05084872
Study type Interventional
Source University Hospital, Toulouse
Contact Maella Severino-Freire, MD
Phone 05 67 77 81 41
Email severino-freire.m@chu-toulouse.fr
Status Not yet recruiting
Phase Phase 2/Phase 3
Start date October 2021
Completion date January 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT01333293 - The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients Phase 2/Phase 3
Completed NCT01481909 - Study on Mastocytosis for Rupatadine Treatment Phase 2/Phase 3
Recruiting NCT00044122 - Study of Factors Regulating Mast Cell Proliferation
Recruiting NCT06440148 - Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis
Recruiting NCT03340155 - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases N/A
Terminated NCT01701843 - Cromoglicate in Mastocytosis Phase 2
Completed NCT00831974 - Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis Phase 2
Completed NCT00047918 - Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing N/A
Completed NCT00006413 - Stem Cell Transplantation to Treat Systemic Mastocytosis Phase 2
Completed NCT00050193 - Cause and Natural Course of Pediatric-Onset Mastocytosis
Completed NCT02620254 - Mast Cell Connect: A Registry for Patients With Mastocytosis
Completed NCT00255346 - Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Phase 2
Completed NCT00001356 - Characteristics of Mast Cells in Mastocytosis N/A
Recruiting NCT06466889 - Mastocytosis Registry (of Zurich)
Recruiting NCT05186753 - (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Phase 2
Completed NCT02478957 - Treatment of Indolent Systemic Mastocytosis With PA101 Phase 2
Recruiting NCT02450396 - Pregnancy and Medically Assisted Conception in Rare Diseases
Completed NCT00038675 - Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate N/A
Not yet recruiting NCT06432556 - Study of Cellular Heterogeneity in Patients With Mastocytosis N/A
Completed NCT00336076 - Molecular Mechanisms and Diagnosis of Mastocytosis N/A